Access the full text.
Sign up today, get DeepDyve free for 14 days.
Xiaohui Zheng, N. Ding, Yuqin Song, Lixia Feng, Jun Zhu (2014)Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
Cancer Cell International, 14
R. Rahal, Mareike Frick, Rodrigo Romero, Joshua Korn, R. Kridel, Fong Chan, B. Meissner, Hyo-eun Bhang, D. Ruddy, A. Kauffmann, Ali Farsidjani, A. Derti, Daniel Rakiec, Tara Naylor, E. Pfister, S. Kovats, Sunkyu Kim, K. Dietze, B. Dörken, C. Steidl, A. Tzankov, M. Hummel, J. Monahan, Michael Morrissey, C. Fritsch, W. Sellers, V. Cooke, R. Gascoyne, G. Lenz, F. Stegmeier (2013)Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
Nature Medicine, 20
N. Saba, Delong Liu, S. Herman, Chingiz Underbayev, X. Tian, David Behrend, M. Weniger, M. Skarzynski, J. Gyamfi, L. Fontán, A. Melnick, C. Grant, M. Roschewski, A. Navarro, S. Beà, S. Pittaluga, K. Dunleavy, W. Wilson, A. Wiestner (2016)Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
Blood, 128 1
D. Tang, Dongcheng Wu, A. Hirao, J. Lahti, Lieqi Liu, B. Mazza, V. Kidd, T. Mak, A. Ingram (2002)ERK Activation Mediates Cell Cycle Arrest and Apoptosis after DNA Damage Independently of p53*
The Journal of Biological Chemistry, 277
E. Campo, S. Rule (2015)Mantle cell lymphoma: evolving management strategies.
Blood, 125 1
A. Inamdar, A. Goy, N. Ayoub, Christen Attia, L. Otón, Varun Taruvai, M. Costales, Yu‐Ting Lin, A. Pecora, Stephen Suh (2016)Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
E. Camacho, L. Hernández, S. Hernández, F. Tort, B. Bellosillo, S. Beà, F. Bosch, E. Montserrat, A. Cardesa, P. Fernandez, E. Campo (2002)ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.
Blood, 99 1
D. Chiron, M. Liberto, P. Martin, Xiangao Huang, J. Sharman, P. Blecua, S. Mathew, P. Vijay, K. Eng, Siraj Ali, A. Johnson, B. Chang, S. Ely, O. Elemento, C. Mason, J. Leonard, S. Chen‐Kiang (2014)Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Cancer discovery, 4 9
Rosaria Chilà, A. Basana, M. Lupi, F. Guffanti, E. Gaudio, A. Rinaldi, L. Cascione, Valentina Restelli, C. Tarantelli, F. Bertoni, G. Damia, L. Carrassa (2014)Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
S. Wuerzberger-Davis, Pei-Yun Chang, C. Berchtold, S. Miyamoto (2005)Enhanced G2-M Arrest by Nuclear Factor-κB-Dependent p21waf1/cip1 Induction
Molecular Cancer Research, 3
P. Ubezio (1985)Microcomputer experience in analysis of flow cytometric DNA distributions.
Computer programs in biomedicine, 19 2-3
S. Beà, M. Ribas, J. Hernández, F. Bosch, M. Pinyol, L. Hernández, J. García, T. Flores, Marcos González, A. López-Guillermo, M. Piris, A. Cardesa, E. Montserrat, R. Miró, E. Campo (1999)Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants.
Blood, 93 12
L. Honigberg, Ashley Smith, M. Sirisawad, E. Verner, D. Loury, B. Chang, Shyr-Jiann Li, Z. Pan, D. Thamm, Richard Miller, J. Buggy (2010)The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Proceedings of the National Academy of Sciences, 107
Valentina Restelli, Rosaria Chilà, M. Lupi, A. Rinaldi, I. Kwee, F. Bertoni, G. Damia, L. Carrassa (2015)Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736
L. Carrassa, Rosaria Chilà, M. Lupi, F. Ricci, Cinzia Celenza, Marco Mazzoletti, M. Broggini, G. Damia (2012)Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo
Cell Cycle, 11
S. Cagnol, J. Chambard (2010)ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescence
The FEBS Journal, 277
Michael Wang, S. Rule, P. Martin, A. Goy, R. Auer, B. Kahl, W. Jurczak, R. Advani, J. Romaguera, Michael Williams, J. Barrientos, E. Chmielowska, J. Radford, S. Stilgenbauer, M. Dreyling, W. Jędrzejczak, Peter Johnson, S. Spurgeon, Lei Li, L. Zhang, K. Newberry, Z. Ou, N. Cheng, B. Fang, J. Mcgreivy, F. Clow, J. Buggy, B. Chang, D. Beaupre, L. Kunkel, K. Blum (2013)Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
The New England journal of medicine, 369 6
L. Carrassa, Y. Sánchez, E. Erba, G. Damia (2009)U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpoint
Journal of Cellular and Molecular Medicine, 13
P. Martin, K. Maddocks, J. Leonard, J. Ruan, A. Goy, N. Wagner-Johnston, S. Rule, R. Advani, D. Iberri, T. Phillips, S. Spurgeon, E. Kozin, Katherine Noto, Zhengming Chen, W. Jurczak, R. Auer, E. Chmielowska, S. Stilgenbauer, J. Bloehdorn, C. Portell, Michael Williams, M. Dreyling, P. Barr, S. Chen‐Kiang, M. Diliberto, R. Furman, K. Blum (2016)Postibrutinib outcomes in patients with mantle cell lymphoma.
Blood, 127 12
D. Tucker, S. Rule (2017)Novel agents in mantle cell lymphoma
Expert Review of Anticancer Therapy, 17
V. Leung-Pineda, C. Ryan, H. Piwnica-Worms (2006)Phosphorylation of Chk1 by ATR Is Antagonized by a Chk1-Regulated Protein Phosphatase 2A Circuit
Molecular and Cellular Biology, 26
S. Zhang, Sonali Smith, S. Zhang, Y. Wang (2015)Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
British Journal of Haematology, 170
C. Cheah, D. Chihara, J. Romaguera, N. Fowler, J. Seymour, F. Hagemeister, R. Champlin, Michael Wang (2015)Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
Annals of oncology : official journal of the European Society for Medical Oncology, 26 6
F. Baran-Marszak, Mohand Boukhiar, S. Harel, C. Laguillier, C. Roger, R. Gressin, Antoine Martin, R. Fagard, N. Varin‐Blank, F. Ajchenbaum‐Cymbalista, D. Ledoux (2010)Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma
M. Dreyling, L. Bullinger, G. Ott, S. Stilgenbauer, H. Müller-hermelink, Martin Bentz, W. Hiddemann, H. Döhner (1997)Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Cancer research, 57 20
S. Rocha, M. Garrett, K. Campbell, K. Schumm, N. Perkins (2005)Regulation of NF‐κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor
The EMBO Journal, 24
D. Colomer, E. Campo (2014)Unlocking new therapeutic targets and resistance mechanisms in mantle cell lymphoma.
Cancer cell, 25 1
N. Vogt, Beiying Dai, Tabea Erdmann, W. Berdel, G. Lenz (2017)The molecular pathogenesis of mantle cell lymphoma
Leukemia & Lymphoma, 58
E. Marostica, J. Sukbuntherng, D. Loury, J. Jong, X. Trixhe, A. Vermeulen, G. Nicolao, S. O'brien, J. Byrd, R. Advani, J. Mcgreivy, I. Poggesi (2014)Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
Cancer Chemotherapy and Pharmacology, 75
L. Quintanilla‐Martinez, T. Davies-Hill, Falko Fend, J. Calzada-Wack, L. Sorbara, Elías Campo, Elaine Jaffe, M. Raffeld (2003)Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis.
Blood, 101 8
A. Goy (2016)Mantle Cell Lymphoma: Is It Time for a New Treatment Paradigm?
Hematology/oncology clinics of North America, 30 6
Background Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma with an unfavorable clinical course. Besides deregulation of the cell cycle, B cell receptor (BCR) signaling, essential for MCL proliferation and survival, is also often deregulated due to constitutive activation of Bruton’s tyrosine kinase (BTK). The BTK inhibitor ibrutinib has been approved as a therapy for refractory MCL, and while it shows some clinical activity, patients frequently develop primary or secondary ibrutinib resistance and have very poor outcomes after relapsing following ibrutinib treatment. Objective To overcome ibrutinib resistance, new therapeutic approaches are needed. As checkpoint kinase 1 (Chk1) inhibitors have recently been shown to be effective as single agents in MCL, we assessed the combination of ibrutinib with Chk1 inhibitors. Methods We examined the activity of ibrutinib combined with the Chk1 inhibitor PF-00477736 in eight MCL cell lines and analyzed underlying cellular and molecular effects. Results The combination was synergistic in all tested cell lines through different mechanisms. The treatment induced apoptosis in ibrutinib-sensitive cell lines, while in ibrutinib-resistant cells the effect was mainly cytostatic and occurred at micromolar concentrations of ibrutinib. Conclusions The pharmacological approach of simultaneously targeting cell cycle checkpoints (by Chk1 inhibitors) and pro- survival
Targeted Oncology – Springer Journals
Published: Feb 13, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.